Published in Drug Week, November 11th, 2005
Durect's net loss for the 3 months ended September 30, 2005, was $3.0 million or 6 cents per share, compared to a net loss of $7.3 million or 14 cents per share for the same period in 2004. DURECT's results for the 3 months ended September 30, 2005, included noncash charges of $363,000 for the amortization of intangible assets and stock-based compensation, compared to $311,000 for the same period in 2004. Cash used in operating activities was $1.1 million for the 3 months ended September 30, 2005, compared to $4.4 million for the same period in 2004.
"We had a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.